active Ankylosing spondylitis (DBCOND0020385)

Identifiers

Synonyms

Active Ankylosing Spondylitis

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Bimekizumab	An anti-IL-17A, IL-17F, and IL-17AF monoclonal antibody used in the treatment plaque psoriasis.	Interleukin-17Atarget Interleukin-17Ftarget
Certolizumab pegol	A tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.	Tumor necrosis factortarget Aldo-keto reductase family 1 member A1enzyme
Golimumab	A TNFα inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.	Tumor necrosis factortarget
Ixekizumab	A monoclonal antibody used to treat moderate to severe plaque psoriasis.	Interleukin-17Atarget
Secukinumab	An immunomodulating agent and interleukin antagonist used to manage plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, along with other joint inflammatory disorders.	Interleukin-17Atarget
Tofacitinib	A Janus kinase (JAK) inhibitor used to treat rheumatic conditions, such as rheumatoid arthritis and ankylosing spondylitis, and ulcerative colitis.	Non-receptor tyrosine-protein kinase TYK2target Cytochrome P450 3A4enzyme Cytochrome P450 2C19enzyme Tyrosine-protein kinase JAK2target Tyrosine-protein kinase JAK1target Tyrosine-protein kinase JAK3target Albumincarrier
Upadacitinib	An oral Janus kinase (JAK)1-selective inhibitor used in the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis, including in patients who did not respond well to other therapies.	Tyrosine-protein kinase JAK1target Cytochrome P450 3A4enzyme Cytochrome P450 2D6enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier organic anion transporter family member 1B1transporter

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04876781	Korean Post-marketing Surveillance for Xeljanz XR	Tofacitinib	Not Available	Not Available	recruiting
NCT05212051	Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS	No drug interventions	treatment	2	unknown_status
NCT03357471	Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease	Certolizumab pegol	treatment	3	completed
NCT05407246	Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis	No drug interventions	treatment	2	completed
NCT05814939	Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.	Tofacitinib	treatment	2	completed